379 related articles for article (PubMed ID: 21990364)
1. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
2. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
3. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
4. IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.
Lee SY; Buhimschi IA; Dulay AT; Ali UA; Zhao G; Abdel-Razeq SS; Bahtiyar MO; Thung SF; Funai EF; Buhimschi CS
J Immunol; 2011 Mar; 186(5):3226-36. PubMed ID: 21282511
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
6. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
7. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis.
Sodenkamp J; Waetzig GH; Scheller J; Seegert D; Grötzinger J; Rose-John S; Ehlers S; Hölscher C
Immunobiology; 2012 Oct; 217(10):996-1004. PubMed ID: 22387074
[TBL] [Abstract][Full Text] [Related]
9. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
10. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C
Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809
[TBL] [Abstract][Full Text] [Related]
13. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T
Heise D; Derrac Soria A; Hansen S; Dambietz C; Akbarzadeh M; Berg AF; Waetzig GH; Jones SA; Dvorsky R; Ahmadian MR; Scheller J; Moll JM
Sci Signal; 2021 Aug; 14(696):. PubMed ID: 34404751
[TBL] [Abstract][Full Text] [Related]
15. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
16. Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.
Lacroix M; Rousseau F; Guilhot F; Malinge P; Magistrelli G; Herren S; Jones SA; Jones GW; Scheller J; Lissilaa R; Kosco-Vilbois M; Johnson Z; Buatois V; Ferlin W
J Biol Chem; 2015 Nov; 290(45):26943-26953. PubMed ID: 26363066
[TBL] [Abstract][Full Text] [Related]
17. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
[TBL] [Abstract][Full Text] [Related]
18. Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19.
Rodríguez-Hernández MÁ; Carneros D; Núñez-Núñez M; Coca R; Baena R; López-Ruiz GM; Cano-Serrano ME; Martínez-Tellería A; Fuentes-López A; Praena-Fernandez JM; Garbers C; Hernández-Quero J; García F; Rose-John S; Bustos M
Front Immunol; 2022; 13():891456. PubMed ID: 35634332
[TBL] [Abstract][Full Text] [Related]
19. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]